article thumbnail

New Treatment Options Available for Patients with Tricuspid Valve Disease

DAIC

In tricuspid valve regurgitation, a complex condition that Cedars-Sinai experts regularly treat, the valve between two heart chambers on the right side doesn't open or close properly. Makkar explained the advances for patients with tricuspid valve disease in a conversationwith the Cedars-Sinai Newsroom. Image by Getty.

article thumbnail

Columbia Cardiology Launches New Mitral & Tricuspid Center

DAIC

Columbia University Irving Medical Center’s Division of Cardiology has announced its launch of the Mitral & Tricuspid Center. Kodali, MD, pictured here, is one of the members of its leadership team, and director of the Structural Heart and Valve Center at CUIMC/NewYork-Presbyterian Hospital.

Tricuspid 111
article thumbnail

TriClip's Tricuspid TEER Cuts Heart Failure Hospitalizations

Med Page Today

(MedPage Today) -- CHICAGO -- Champions of tricuspid transcatheter edge-to-edge repair (TEER) were buoyed by 2-year results of the TRILUMINATE trial marking the first report of reduced heart failure (HF) hospitalization for this technology.

article thumbnail

Henry Ford Health Heart Failure Patient First in Michigan to Receive Breakthrough Device

DAIC

Henry Ford Health's Center for Structural Heart Disease team delivered its first in Michigan FDA-approved VOQUE Transcatheter Tricuspid Valve Replacement System to a heart failure patient on February 13, 2024 at Henry Ford Hospital in Detroit. million Americans have moderate to severe tricuspid regurgitation.

article thumbnail

FDA Advisory Committee Votes in Favor of Abbott’s First-of-its-kind Triclip System to Treat People with a Leaky Tricuspid Heart Valve

DAIC

Food and Drug Administration ( FDA ) confirmed 13 to 1, with 0 abstention that the benefits of Abbott's TriClip™ transcatheter edge-to-edge repair (TEER) system outweighed the risks for the treatment of people with tricuspid regurgitation (TR). On the final question of the benefit of TriClip versus the risk, the vote was 13 to 1 in favor.

Tricuspid 102
article thumbnail

Edwards’ EVOQUE Valve Replacement System First Transcatheter Therapy to Earn FDA Approval for Tricuspid Valve

DAIC

Photo: Edwards Lifesciences milla1cf Fri, 02/02/2024 - 09:33 February 2, 2024 — Edwards Lifesciences Corporation announced the company’s EVOQUE tricuspid valve replacement system is the first transcatheter therapy to receive U.S. Food and Drug Administration (FDA) approval for the treatment of tricuspid regurgitation (TR).

Tricuspid 100
article thumbnail

The Tricuspid Valve: A Review of Pathology, Imaging, and Current Treatment Options: A Scientific Statement From the American Heart Association

Circulation

Tricuspid valve disease is an often underrecognized clinical problem that is associated with significant morbidity and mortality. Unfortunately, patients will often present late in their disease course with severe right-sided heart failure, pulmonary hypertension, and life-limiting symptoms that have few durable treatment options.